BRCA2 and neoplasm: However, there were no differences in ER status, tumor size, stage, parity (among parous groups), age at menarche, distribution of BRCA1 or BRCA2 PVs, or type of PV (ie, copy number variants, truncating, splice site, missense PVs, and promoter alterations) across groups (Table 1).